Q1 2025 Performance Highlights - EVgo's network throughput reached 83 GWh, a 60% increase compared to Q1 2024[11] - EVgo's revenue totaled $75 million, a 36% increase compared to Q1 2024[11] - EVgo operated 4,240 stalls, a 32% increase with 180 new stalls added[11] Tariff Impact and Capex Efficiencies - The estimated tariff impact on EVgo's 2025 capex spend is $4 million to $5 million[14] - EVgo anticipates $10 million in capex efficiencies, offsetting the tariff impact in 2025[14] - 75% of capex per stall has no exposure to tariffs[13] Market Dynamics - US non-Tesla EV sales grew 36% year-over-year in Q1 2025[15] - EVgo gained market share due to flat DCFC supply growth for 7 quarters[16] Financial Outlook - EVgo projects revenue between $340 million and $380 million for 2025[74] - EVgo anticipates adjusted EBITDA between negative $5 million and positive $10 million for 2025[74]

Q1 2025 Performance - Sales decreased slightly to $827 million, a 0.3% decrease compared to Q1 2024 [9] - Adjusted EBITDA increased by 1.1% to $145 million, with an adjusted EBITDA margin of 17.5% [9] - Adjusted EPS remained flat at $0.76, in line with guidance [9] - Organic sales growth varied by region, with US & Canada down by 3%, Europe, Middle East & Africa up by 2%, Asia up by 9%, and Latin America up by 17% [10] Segment Performance - Color, Additives & Inks sales increased to $520 million from $515 million in Q1 2024, with an adjusted EBITDA margin of 19.3% [15] - Specialty Engineered Materials sales decreased to $308 million from $314 million in Q1 2024, with an adjusted EBITDA margin of 22.2% [18] Financial Guidance for 2025 - The company maintains its full-year 2025 adjusted EBITDA guidance of $540 to $570 million, representing a 4% to 10% growth excluding foreign exchange impacts [26] - Full-year 2025 adjusted EPS guidance is $2.70 to $2.94 [26] - Q2 2025 adjusted EPS is expected to be $0.79 [26] Sales Exposure - Sales exposure is approximately $100 million [23] - Raw materials exposure is approximately $100 million [23]

Financial Performance - Total revenues increased by 164% to $28224 million in Q1 2025 from $242449 million in Q1 2024[23] - System-wide sales increased 115% to $3230 million in Q1 2025 from $289581 million in Q1 2024[23] - Same-restaurant sales growth was 07%[23] - Restaurant level operating profit margin decreased to 165% in Q1 2025 from 208% in Q1 2024[23] - Adjusted EBITDA decreased to $22753 million in Q1 2025 from $28590 million in Q1 2024[23] - Net loss was $(08) million in Q1 2025, compared to a net income of $7214 million in Q1 2024[23] Expansion and Outlook - The company opened 13 system-wide restaurants and closed 1, resulting in 584 system-wide restaurants across 30 states[23] - The company projects total revenue growth of approximately 200% for fiscal year 2025[51] - The company anticipates opening 59 to 64 new system-wide restaurants, net of 3 company-owned closures[51] - Adjusted EBITDA is projected to be in the range of $1140 million to $1190 million[51]

Earnings Presentation First Quarter 2025 Forward-Looking Statements and Disclaimer Forward Looking Statements This presentation contains forward-looking statements related to the operations of the Partnership that are based on management's current expectations, estimates, and projections about its operations. You can identify many of these forward-looking statements by words such as "believe," "expect," "intend," "project," "anticipate," "estimate," "continue," "if," "outlook," "will," "could," "should," or ...

Q2 Fiscal 2025 Highlights - Revenue increased by 2%[8] - Organic Revenue increased by 3%[8] - Operating Income increased by 9%[8] - Adjusted Operating Income (AOI) increased by 11%[8] - GAAP EPS increased by 15%[10] - Adjusted EPS increased by 22%[10] Revenue Growth Across Segments - Aramark's organic revenue growth was 3%[13] - FSS United States organic revenue growth was 1%[15] - FSS International organic revenue growth was 10%[17] Fiscal 2025 Outlook - The company anticipates organic revenue growth between 75% and 95%[35] - Adjusted Operating Income is expected to grow between 15% and 18%[35] - Adjusted EPS is projected to increase between 23% and 28%[35] - The target leverage ratio is approximately 30x by the end of the fiscal year[30, 35]

Q1 2025 Financial Performance - Q1 2025 revenue reached $662 million, reflecting a 7% growth in constant currency[6] - Recurring revenue experienced an 11% growth in constant currency[6] - Instrument sales increased by 4% as reported and 11% in constant currency[6] - Non-GAAP EPS for Q1 2025 was $2.25, a 2% increase, with a 7% growth in constant currency[6] Growth Drivers and Market Segmentation - Instrument sales showed strong growth, with Pharma up 14%, Industrial up 10%, and Academic & Government up 7% in constant currency[9] - Asia showed the strongest geographic growth at 13%, followed by the Americas at 6%, and Europe at 1% in constant currency[19] - Waters segment grew 8% while TA segment grew 1%[19] Innovation and Idiosyncratic Growth - Next-Gen Flagship HPLC sales grew over 3 times year-over-year, representing approximately 20% of HPLC sales[14] - Waters Xevo TQ Absolute sales grew 56% year-over-year[14] - QA/QC testing of GLP-1 drugs is expected to contribute an average 30bps growth annually from 2024 to 2030[15] - PFAS testing is a $400 million global market, estimated to grow approximately 20%[15] FY & Q2 2025 Guidance - The company projects constant currency revenue growth of +5% to +7% for FY 2025 and Q2 2025[21] - The company projects Non-GAAP EPS of $12.75 to $13.05 for FY 2025 and $2.88 to $2.98 for Q2 2025[21]

Financial Performance - Leidos' Q1 FY25 revenues increased by 6.8% year-over-year, reaching $4.245 billion compared to $3.975 billion in Q1 FY24 [22] - The adjusted EBITDA margin for Q1 FY25 was 14.2%, a 190 basis points increase from 12.3% in Q1 FY24 [22] - Non-GAAP diluted EPS for Q1 FY25 rose by 29.7% year-over-year, from $2.29 to $2.97 [22] - Operating cash flow was $58 million and non-GAAP free cash flow was $36 million [25] Segment Results - National Security & Digital segment revenue increased by 4.7%, from $1.793 billion to $1.878 billion [24] - Health & Civil segment revenue increased by 7.7%, from $1.199 billion to $1.291 billion [24] - Commercial & International segment revenue increased by 11.6%, from $509 million to $568 million [24] - Defense Systems segment revenue increased by 7.2%, from $474 million to $508 million [24] Capital Allocation and Guidance - Leidos executed a $500 million accelerated share repurchase [17, 25] - Leidos reaffirmed its FY25 revenue guidance of $16.90 - $17.30 billion [27] - The company reaffirmed its FY25 adjusted EBITDA margin guidance in the mid-high 12% range [27]

May 6, 2025 First Quarter 2025 Financial Results Ray Scott, President and CEO Jason Cardew, Senior Vice President and CFO Lear Proprietary: The information contained herein is the property of Lear Corporation. Safe Harbor Statement Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding anticipated financial results and liquidity. The words "will," "may," "designed to," "outloo ...

May 6, 2025 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements regarding MPC. These forward-looking statements may relate to, among other things, MPC's expectations, estimates and projections concerning its business and operations, financial priorities, strategic plans and initiatives, capital return plans, capital expenditure plans, operating cost reduction objectives, and environmental, social and governance ("ESG") plans and goals, including those related to greenhouse gas e ...

First Quarter 2025 Financial Results Non-IFRS financial information is presented for supplemental informational purposes only and should not be considered in isolation or as a substitute for financial information presented in accordance with IFRS. Our presentation of Non-IFRS measures should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items. Other companies in our industry may calculate these measures differently, which may limit their usefulness as ...